Jun 2026 (Q2 FY26) — Jul 30, 2026
Vericel Q2 FY26 — Record Revenue and Raised Full-Year Guidance
Read the full callVericel (VCEL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Vericel earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 77.5 | +22.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 0.6 | +3.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 2.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$40.37 +0.60% · +$0.24
Performance +14.3% 1Y
1Y: $35.32 on 17 Oct 2025 → $40.37. High $48.31 (9 Jul 2026), low $29.34 (27 Mar 2026).
- Previous close
- $40.13
- 52-week range
- $29.34 – $48.31
- One year
- +12.08%
Overview
- Symbol
- VCEL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Vericel earnings calls (VCEL)
Financials
What the filings say
Net profit, year on year: +499% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 58 | 75 | 53 | 63 | 68 | 93 | 68 | 77 |
| Operating profit | -2 | 18 | -13 | -2 | 3 | 22 | -8 | 0 |
| Operating margin | −4.3% | 24.5% | −24.3% | −3.2% | 5.1% | 24.1% | −11.8% | 0.6% |
| Other income | 2 | 1 | 2 | 1 | 2 | 2 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -1 | 20 | — | — | — | — | — | — |
| Tax rate | 0.0% | 0.7% | — | — | — | — | — | — |
| Net profit | -1 | 20 | -11 | -1 | 5 | 23 | -6 | 2 |
| EPS ($ per share) | -0.02 | — | -0.23 | -0.01 | 0.10 | — | -0.12 | 0.04 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 471 | 490 | 510 | 554 | 593 | 629 | 685 | 731 |
| Reserves | -369 | -379 | -376 | -383 | -400 | -403 | -393 | -376 |
| Total liabilities | 16 | 42 | 71 | 73 | 81 | 128 | 141 | 133 |
| Fixed assets | 6 | 7 | 8 | 13 | 16 | 42 | 103 | 108 |
| Investments | 65 | 43 | 42 | 35 | 68 | 40 | 42 | 37 |
| Total assets | 119 | 153 | 206 | 244 | 273 | 354 | 433 | 488 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0 | -7 | 18 | 29 | 18 | 35 | 58 | 52 |
| Cash from investing | -67 | 11 | -17 | -4 | -36 | -3 | -79 | -44 |
| Cash from financing | 59 | 5 | 6 | 9 | 1 | 4 | 19 | 7 |
| Net cash flow | -9 | 9 | 7 | 35 | -17 | 36 | -2 | 15 |
| Capital expenditure | -3 | -3 | -3 | -8 | -8 | -20 | -64 | -27 |
| Free cash flow | -3 | -10 | 15 | 21 | 10 | 15 | -6 | 25 |
Insider filings
111 filings between Nov 6, 2025 and Aug 12, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$7.89M
34 sales by 8 insiders
88% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 56
- Option exercise — converted options into shares
- 21
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Halpin Michael | — | $2.04M | Aug 3, 2026 |
| Flynn Sean C. | — | $2.04M | Jun 26, 2026 |
| MCLAUGHLIN KEVIN F | — | $1.05M | Aug 12, 2026 |
| Hopper Jonathan Mark | — | $789.3K | Jun 26, 2026 |
| SIEGAL JONATHAN | — | $530.8K | Jul 30, 2026 |
| Wotton Paul K | — | $516.9K | May 11, 2026 |
| Hagen Heidi | — | $486.1K | Mar 23, 2026 |
| Mara Joseph Anthony Jr | — | $426.3K | Jun 26, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 12, 2026 | MCLAUGHLIN KEVIN F Director | Option exercise 10b5-1 plan | 7,000 | $91.3K |
| Aug 12, 2026 | MCLAUGHLIN KEVIN F Director | Sale 10b5-1 plan | 7,000 | $311.7K |
| Aug 3, 2026 | Halpin Michael Chief Operating Officer | Option exercise 10b5-1 plan | 10,000 | $166.6K |
| Aug 3, 2026 | Halpin Michael Chief Operating Officer | Sale 10b5-1 plan | 10,000 | $468.4K |
| Jul 30, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Option exercise 10b5-1 plan | 2,500 | $74.5K |
| Jul 30, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Sale 10b5-1 plan | 1,500 | $73.3K |
| Jul 30, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Sale 10b5-1 plan | 500 | $24.4K |
| Jul 30, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Sale 10b5-1 plan | 2,500 | $122.3K |
| Jul 30, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Option exercise 10b5-1 plan | 500 | $14.9K |
| Jul 30, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Option exercise 10b5-1 plan | 1,500 | $52.4K |
| Jun 26, 2026 | Hopper Jonathan Mark Chief Medical Officer | Sale 10b5-1 plan | 5,000 | $225.0K |
| Jun 26, 2026 | Flynn Sean C. Chief Legal Officer | Sale 10b5-1 plan | 15,000 | $684.6K |
| Jun 26, 2026 | Hopper Jonathan Mark Chief Medical Officer | Sale 10b5-1 plan | 5,000 | $225.0K |
| Jun 26, 2026 | Hopper Jonathan Mark Chief Medical Officer | Option exercise 10b5-1 plan | 5,000 | $149.1K |
| Jun 26, 2026 | Flynn Sean C. Chief Legal Officer | Option exercise 10b5-1 plan | 15,000 | $243.8K |
| Jun 26, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Option exercise 10b5-1 plan | 2,500 | $74.5K |
| Jun 26, 2026 | Hopper Jonathan Mark Chief Medical Officer | Option exercise 10b5-1 plan | 5,000 | $149.1K |
| Jun 26, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Sale 10b5-1 plan | 232 | $10.4K |
| Jun 26, 2026 | Mara Joseph Anthony Jr Chief Financial Officer | Sale 10b5-1 plan | 5,000 | $223.8K |
| Jun 26, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Sale 10b5-1 plan | 2,500 | $112.3K |
| Jun 18, 2026 | Halpin Michael Chief Operating Officer | Sale 10b5-1 plan | 10,000 | $402.4K |
| Jun 18, 2026 | Flynn Sean C. Chief Legal Officer | Option exercise 10b5-1 plan | 15,000 | $243.8K |
| Jun 18, 2026 | Halpin Michael Chief Operating Officer | Option exercise 10b5-1 plan | 10,000 | $166.6K |
| Jun 18, 2026 | Flynn Sean C. Chief Legal Officer | Sale 10b5-1 plan | 15,000 | $603.1K |
| Jun 2, 2026 | Hopper Jonathan Mark Chief Medical Officer | Option exercise 10b5-1 plan | 4,375 | $72.9K |
| Jun 2, 2026 | Hopper Jonathan Mark Chief Medical Officer | Sale 10b5-1 plan | 4,375 | $153.1K |
| May 13, 2026 | MCLAUGHLIN KEVIN F Director | Option exercise 10b5-1 plan | 3,500 | $45.7K |
| May 13, 2026 | MCLAUGHLIN KEVIN F Director | Sale 10b5-1 plan | 3,500 | $114.9K |
| May 13, 2026 | MCLAUGHLIN KEVIN F Director | Option exercise 10b5-1 plan | 3,500 | $9.2K |
| May 13, 2026 | MCLAUGHLIN KEVIN F Director | Sale 10b5-1 plan | 3,500 | $114.9K |
| May 11, 2026 | Wotton Paul K Director | Sale | 7,500 | $244.8K |
| May 11, 2026 | Wotton Paul K Director | Sale | 2,500 | $82.6K |
| May 7, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Sale 10b5-1 plan | 1,422 | $57.6K |
| May 7, 2026 | Mara Joseph Anthony Jr Chief Financial Officer | Sale 10b5-1 plan | 5,000 | $202.5K |
| May 6, 2026 | SIEGAL JONATHAN Principal Accounting Officer | Sale 10b5-1 plan | 3,433 | $130.5K |
| Apr 29, 2026 | WRIGHT LISA Director | Option exercise | 3,200 | — |
| Apr 29, 2026 | MCLAUGHLIN KEVIN F Director | Option exercise | 3,200 | — |
| Apr 29, 2026 | Hagen Heidi Director | Option exercise | 3,200 | — |
| Apr 29, 2026 | Rubino Alan L Director | Option exercise | 3,200 | — |
| Apr 29, 2026 | Wotton Paul K Director | Option exercise | 3,200 | — |
| Apr 29, 2026 | ZERBE ROBERT L MD Director | Option exercise | 3,200 | — |
| Apr 2, 2026 | Hopper Jonathan Mark Chief Medical Officer | Option exercise 10b5-1 plan | 3,472 | $38.0K |
| Apr 2, 2026 | Hopper Jonathan Mark Chief Medical Officer | Sale 10b5-1 plan | 3,472 | $121.5K |
| Mar 25, 2026 | Rubino Alan L Director | Option exercise | 15,000 | $41.4K |
| Mar 23, 2026 | Hagen Heidi Director | Sale 10b5-1 plan | 15,000 | $486.1K |
| Mar 23, 2026 | Hagen Heidi Director | Option exercise 10b5-1 plan | 15,000 | $41.4K |
| Mar 2, 2026 | Flynn Sean C. Chief Legal Officer | Sale 10b5-1 plan | 15,000 | $530.4K |
| Mar 2, 2026 | Flynn Sean C. Chief Legal Officer | Option exercise 10b5-1 plan | 15,000 | $243.8K |
| Mar 2, 2026 | Flynn Sean C. Chief Legal Officer | Sale 10b5-1 plan | 6,421 | $223.1K |
| Mar 2, 2026 | Halpin Michael Chief Operating Officer | Sale 10b5-1 plan | 10,305 | $363.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Vericel Corp
Free account. Everything above stays public.
Write why you follow Vericel Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading